Market Overview

UPDATE: Stifel Nicolaus Upgrades BioMarin Pharmaceutical on Catalysts

Related BMRN
BioMarin's Initial 6-Month Data From Phase 2 Study of Vosoritide (BMN 111) in Children With Achondroplasia Presented at the American Society for Bone and Mineral Research Annual 2015 Meeting
Leerink Chats With Biotech Management, Names 20 Stocks To Buy Now
BioMarin Presents Data on Vosoritide at Medical Meeting (Zacks)

Stifel Nicolaus upgraded BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) from Hold to Buy and announced a $67.00 price target.

Stifel Nicolaus commented, "We believe anticipation around a YE13 GALNS launch provides a tangible floor in valuation near-term and are increasingly comfortable with PEG-PAL-associated value longer-term. While acknowledging visibility into BMN-701 expansion cohort data remains limited, we believe the pipeline provides multiple additional sources of optionality to drive upside in FY13. We believe the company represents an attractive acquisition candidate near-term while also being one of the few (if any) names that seemingly has a sustainable pathway in place to independently achieve large-cap status longer-term."

BioMarin Pharmaceutical closed at $54.08 on Friday.

Latest Ratings for BMRN

Oct 2015Raymond JamesInitiates Coverage onOutperform
Aug 2015JefferiesMaintainsBuy
Aug 2015Deutsche BankMaintainsBuy

View More Analyst Ratings for BMRN
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Upgrades Intraday Update Analyst Ratings


Related Articles (BMRN)

View Comments and Join the Discussion!

Get Benzinga's Newsletters